memoria2015

3
INCLIVA
Global analysis
30
Besides research network structures, INCLIVA joined three
additional research platforms promoted by Carlos III Health Institute
which started their activities in 2014. These platforms are
Biobank, Clinical research and trials and Innovation.
Reference: PT13/0010/0004
Title: Biobank Platform
Principal Investigator: Josep Redón I Mas
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación Investigación Hospital Clínico
Universitario de Valencia
Duration: 2014 - 2016
Total budget: 46.500€
Reference: PT13/0002/0031
Title: Clinical Research and Trials Platform
Principal Investigator: Andrés Cervantes Ruipérez
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación Investigación Hospital Clínico
Universitario de Valencia
Duration: 2014 - 2016
Total budget: 65.550€
Reference: PT13/0006/0023
Title: Innovation Platform
Principal Investigator: Josep Redón I Mas
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación Investigación Hospital Clínico
Universitario de Valencia
Duration: 2014 - 2016
Total budget: 38.985€
3.4 Knowledge transfer to the National
Health System
INCLIVA Health Research Institute is fully committed to
innovation in health and to transfer knowledge to both the
National Health System and the industrial sector in order to fulfil
its organizational mission.
3.4.1 Knowledge transfer to the Health System
Clinical guidelines and consensus documents are one of the
best indicators of transference from research to clinical practice
improvement. The following table shows guidelines published
in indexed journals in which authors attached to INCLIVA have
participated.
Clinical guidelines
IF
21 117,67
1. Grupo de expertos del Grupo de Estudio sobre Alteraciones
Metabólicas (GEAM), de la Secretaría del Plan Nacional
sobre el Sida (SPNS) y del Grupo de Estudio de Sida
(GeSIDA), Polo Rodríguez R, Galindo Puerto MJ, Dueñas C,
Gómez Candela C, Estrada V, Villar NG, Locutura J, Mariño A,
Pascua J, Palacios R, von Wichmman MÁ, Álvarez J, Asensi
V, López Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol E,
Gutiérrez F, Sanz Sanz J, Martínez Chamorro E. [Consensus
statement on metabolic disorders and cardiovascular risks
in patients with human immunodeficiency virus].Enferm
Infecc Microbiol Clin. 2015 Jan ;33(1):40.e1-40.e16.IF: 1,881
2. Panel of experts from the Metabolic Disorders Study Group
(GEAM), National Aids Plan (SPNS), Aids Study Group
(GeSIDA), Polo Rodríguez R, Galindo Puerto MJ, Dueñas C,
Gómez Candela C, Estrada V, Villar NG, Locutura J, Mariño A,
Pascua J, Palacios R, Von Wichmman MÁ, Álvarez J, Asensi
V, López Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol
E, Gutiérrez F, Sanz Sanz J, Martínez Chamorro E. Executive
summary of the consensus document on metabolic disorders
and cardiovascular risk in patients with HIV infection.Enferm
Infecc Microbiol Clin. 2015 Jan; 33(1):41-7.IF: 1,881
3. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans
P, Rutgers E, Zackrisson S, Cardoso F, ESMO Guidelines